Contents
Editor’s Letter
Latest features in GaBI Journal, 2013, Issue 3
Editorial
Italy’s final position paper on biosimilars and new price and reimbursement pathway
Commentary
Biosimilar monoclonal antibodies—challenges and opportunities in Europe
Original Research
Regional tenders on biosimilars in Italy: potentially competitive?
Assessing biosimilarity using the method of generalized pivotal quantities
Review Article
Steps to ensure adequate supply of biological medicines: considerations for the healthcare provider
Safety and toxicity of biosimilars—EU versus US regulation
Perspective
Licensing and prescribing biosimilars in Australia
Regulatory
US state legislation on biosimilars substitution
Abstracted Scientific Content
Biosimilar monoclonal antibodies – time for a regulatory rethink